[Hamostasiological changes induced by platelet-aggregation-inhibitors, tested in children with congenital heart disease (in vitro and in vitro examinations) (author's transl)].
This report has delt with in vivo and in vitro examinations in the cases of sixteen children suffering from cyanotic congenital heart disease, and who had been placed under extended therapy with platelet-aggregation-inhibitors. The pharmacological effect of acetylsalicylic acid and dipyridamol has been discussed--as far as it is known. The discrepancy between in vivo and in vitro therapy-effect in the treatment with platelet-aggregation-inhibitors has been subjected to criticism. Consistant treatment of all children suffering from cyanotic congenital heart disease with aspirine and persantine has been advocated, however should only be carried out in collaboration with a competent hamostasiological laboratory.
D000293:Adolescent; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003490:Cyanosis; D004176:Dipyridamole / Q000494:pharmacology* / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D013997:Time Factors
D004176:Dipyridamole; D001241:Aspirin
Hämostaseveränderungen durch Plättchenaggregationshemmer bei Kindern mit Herzvitien (in vivo- und in vitro-Untersuchungen)